Sign In
Buy VCEL
$34.74
+0.290 (+0.84%)
At Close: Jun 03, 2026
Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025
08:30am, Thursday, 28'th Aug 2025
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Com
Vericel Q2 Revenue Jumps 20%
03:14pm, Tuesday, 05'th Aug 2025
Vericel Q2 Revenue Jumps 20%
Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates
10:16am, Thursday, 31'st Jul 2025
Vericel Corporation (VCEL) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.1 per share a year ago.
Vericel Reports Second Quarter 2025 Financial Results
08:08am, Thursday, 31'st Jul 2025
Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million,
Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025
08:30am, Thursday, 17'th Jul 2025
CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Com
Vericel Corporation: Moving From Sell To Neutral
10:23am, Thursday, 12'th Jun 2025
Vericel's valuation has moderated after a 20% share price drop, prompting a shift from sell to neutral. MACI remains the company's primary growth engine, with strong sales momentum and successful surg
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025
08:30am, Tuesday, 10'th Jun 2025
CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Com
Vericel Corporation (VCEL) Q1 2025 Earnings Conference Call Transcript
01:52pm, Thursday, 08'th May 2025
Vericel Corporation. (NASDAQ:VCEL ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Eric Burns - VP, Finance and IR Nick Colangelo - CEO Joe Mara - CFO Conference Call Par
Vericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue Estimates
10:05am, Thursday, 08'th May 2025
Vericel Corporation (VCEL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago.
Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
07:55am, Thursday, 08'th May 2025
Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 Million Approximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for
Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025
08:30am, Wednesday, 07'th May 2025
CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Comp
Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025
08:30am, Thursday, 24'th Apr 2025
CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Co
Vericel: Scalable Growth With Strong Margins
11:56pm, Wednesday, 05'th Mar 2025
Vericel's niche in regenerative medicine is undervalued, with FDA-approved products like MACI, Epicel, and NexoBrid driving steady revenue growth and profitability. The company's strong financials inc
Vericel to Present at Multiple Upcoming Investor Conferences
08:30am, Tuesday, 04'th Mar 2025
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Co
Vericel Corporation (VCEL) Q4 2024 Earnings Conference Call Transcript
01:05pm, Thursday, 27'th Feb 2025
Vericel Corporation (NASDAQ:VCEL ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Nick Colangelo - CEO Joe Mara - CFO Eric Burns - VP, Finance and IR Conference Cal
